Tmozolmide 250 & Temozolomide (250 mg).Uses, Dosage, and Side Effects .Steris Healthcare PVT LTD....

Tmozolmide 250

Temozolomide (250 mg)

Tmozolmide 250 is a high-dosage formulation of Temozolomide250mg, an essential chemotherapeutic agent used in the treatment of certain aggressive brain cancers. Known for its ability to penetrate the blood-brain barrier, Temozolomide is particularly effective in managing glioblastoma multiforme and anaplastic astrocytoma. Tmozolmide 250 provides a robust treatment option for patients requiring higher dosages to combat their malignancies effectively.

Composition

• Active Ingredient: Temozolomide (250mg)
• Excipients: Lactose anhydrous, sodium starch glycolate, tartaric acid, stearic acid, and other inactive ingredients that ensure the stability and effectiveness of the capsule.

Mechanism of Action

Temozolomide is an oral alkylating agent that quickly converts to its active form, MTIC (methyl-triazeno-imidazole-carboxamide), upon ingestion. MTIC works by methylating the DNA of cancer cells, specifically at the O6 and N7 positions of guanine residues. This methylation leads to DNA damage, interrupting the cancer cells' replication process and triggering cell cycle arrest and apoptosis. This mechanism is highly effective against rapidly dividing tumor cells.

Indications

Tmozolmide 250 is indicated for:

• Newly Diagnosed Glioblastoma Multiforme: Used alongside radiotherapy and as maintenance therapy.
• Refractory Anaplastic Astrocytoma: For patients whose disease has progressed despite prior therapy.
• Off-Label Uses: Occasionally used for other malignancies, such as metastatic melanoma and certain sarcomas, under the guidance of an oncologist.

Dosage and Administration

• Standard Dosage: For newly diagnosed glioblastoma, the initial dose is 75mg/m² daily for 42 days in conjunction with radiotherapy, followed by maintenance therapy of 150-200mg/m² once daily for 5 days in a 28-day cycle.
• Administration: Tmozolmide 250 should be taken on an empty stomach to enhance absorption, preferably at the same time each day.
• Dose Adjustments: Dosage may be adjusted based on patient response and tolerability, with close monitoring for hematologic and non-hematologic toxicities.

Benefits

• Blood-Brain Barrier Penetration: One of the few chemotherapeutic agents that can effectively cross the blood-brain barrier, providing direct treatment to brain tumors.
• Improved Survival Rates: Proven to improve overall survival and progression-free survival in patients with glioblastoma.
• Convenient Oral Administration: Easier for patients to take compared to intravenous chemotherapeutic agents, enhancing compliance and quality of life.

Side Effects

While Tmozolmide 250 is highly effective, it can cause several side effects, including:

• Hematologic Toxicity: Myelosuppression, including neutropenia, thrombocytopenia, and anemia, is common and requires regular blood monitoring.
• Gastrointestinal Issues: Nausea, vomiting, and loss of appetite are frequent but can often be managed with supportive care.
• Fatigue: Many patients experience significant fatigue during treatment.
• Liver Toxicity: Potential for elevated liver enzymes, necessitating periodic liver function tests.
• Increased Infection Risk: Due to immunosuppression, patients are more susceptible to infections and should take precautions to avoid exposure to pathogens.

Precautions and Warnings

• Regular Monitoring: Patients should undergo regular blood tests to monitor blood cell counts and liver function.
• Contraindications: Not recommended for patients with severe bone marrow suppression or known hypersensitivity to Temozolomide.
• Drug Interactions: Caution is advised when combining Temozolomide with other myelosuppressive agents or medications that can increase the risk of liver toxicity.
• Pregnancy and Nursing: Temozolomide is teratogenic and should not be used during pregnancy. Women of childbearing potential should use effective contraception, and breastfeeding is contraindicated during treatment.

Conclusion

Tmozolmide 250, with its high dosage of Temozolomide, offers a powerful treatment option for aggressive brain cancers such as glioblastoma multiforme and anaplastic astrocytoma. Its ability to cross the blood-brain barrier and directly target cancer cells within the central nervous system makes it an invaluable asset in oncology. Despite the potential for significant side effects, the benefits of improved survival and tumor control make Tmozolmide 250 a cornerstone in the treatment of malignant brain tumors. With careful monitoring and adherence to prescribed guidelines, patients can achieve optimal outcomes in their battle against these challenging cancers.Steris Healthcare Pvt Ltd, founded by a group of expert professionals in the pharmaceutical industry in February 2018, operates as Sterispharma. This company, which is based in Navi Mumbai, holds certifications from WHO, GMP, and ISO. Its commitment is to provide high-quality drugs at affordable prices to its customers throughout India, following the rigorous guidelines set by the WHO. Steris offers the convenience of an online pharmacy where customers can easily buy medicines and enjoy the benefit of home delivery. At Steris, the mission is to supply a wide array of healthcare products designed to meet the varied needs of the medical community. Whether it is advanced treatments, medications for rare conditions, or basic health necessities, Sterispharma strives to serve the healthcare industry’s broad demands. The extensive product lineup from Steris includes treatments for various health areas such as Cardiology, Asthma, Respiratory issues, Nasal conditions, Diabetes, Endocrinology, Gastroenterology, Orthopedics, Anti-infectives/antibiotics, General Medicine, Urology, Neurology, Nephrology, Oncology, Gynecology, Pediatrics, Dental care, and Dermatology.

For further information: 

EMAIL:  info@sterispharma.com  / contact@sterispharma.com   

CALL/WHATSAPP: 7877551268, 7849827488

BUY NOW